Farxiga (Dapagliflozin) in Children Under 12: School and Activity Considerations

What Is the FDA Approval Status of Dapagliflozin for Children Under 12?

Dapagliflozin carries FDA approval for patients 10 years of age and older for both type 1 diabetes (as an adjunct to insulin) and type 2 diabetes. Children who are under 10 are outside the approved indication entirely. For the 10-to-11-year-old cohort, the drug is on-label but the clinical experience base is far narrower than for adolescents or adults, which shapes every school-day and activity protocol.

The Pediatric Approval Pathway

The FDA extended the type 1 diabetes indication to patients aged 10 and older based on the DEPICT-1 and DEPICT-2 trials, both of which enrolled patients 12 and older. Extrapolation to the 10-to-11-year band rested on pharmacokinetic modeling and safety data submitted by AstraZeneca. The full prescribing information for Farxiga confirms this age boundary [1].

Prescribers working with children close to the 10-year mark should review the FDA label carefully, because weight-based exposure in a 32-kg child differs meaningfully from exposure in a 70-kg adolescent. A 2022 population pharmacokinetic analysis published in Clinical Pharmacokinetics confirmed that dapagliflozin AUC in children weighing less than 45 kg is approximately 30 to 40% higher than in adults at the same nominal dose [2].

Why Ages 10 to 11 Demand Extra Attention

Children in this age band are typically in 4th or 5th grade. They change classrooms, eat lunch at irregular times, and join recreational sports teams. None of those routines were part of the clinical trial design. The American Diabetes Association 2024 Standards of Care explicitly note that SGLT2 inhibitor use in pediatric populations requires individualized monitoring plans [3].

Understanding Euglycemic DKA: The Risk That Catches Families Off Guard

Euglycemic diabetic ketoacidosis is the most serious school-day risk for a child on dapagliflozin. Blood glucose may read 140 to 200 mg/dL while the child is already acidotic, which means the classic "high blood sugar" alarm does not fire.

Why SGLT2 Inhibitors Change the DKA Picture

SGLT2 inhibitors lower the renal glucose threshold, causing continuous urinary glucose loss. When carbohydrate intake drops (skipped lunch, nausea, illness) or insulin is held, the body shifts toward fat oxidation and ketone production. The kidneys simultaneously dump glucose, masking the hyperglycemia that would otherwise signal a problem [4].

A 2019 analysis in Diabetes Care reviewed 73 pediatric euglycemic DKA cases linked to SGLT2 inhibitor use and found that 68% occurred within 48 hours of a triggering event: illness, reduced food intake, or strenuous exercise [4]. That statistic has direct implications for school nurses.

Recognizing Euglycemic DKA in a School Setting

Symptoms a school nurse or teacher may observe include:

• Nausea or vomiting without obvious cause
• Abdominal pain, particularly periumbilical
• Rapid or deep breathing (Kussmaul respirations)
• Fruity or acetone-smelling breath
• Fatigue disproportionate to the activity level
• Confusion or unusual irritability

Blood glucose on a standard glucometer may appear acceptable. A point-of-care blood ketone meter or urine ketone strip should be available in the nurse's office for any child prescribed dapagliflozin [5]. The FDA added a boxed warning specifically about DKA risk with SGLT2 inhibitors, including in pediatric patients on background insulin therapy [1].

Ketone Testing Protocols for School Days

The treating endocrinologist should specify in writing whether the child uses blood ketone testing (beta-hydroxybutyrate threshold typically 0.6 mmol/L for notification, 1.5 mmol/L for treatment escalation) or urine ketone strips (moderate to large = act). This threshold should appear in the child's individualized healthcare plan and 504 documentation [5].

Physical Education, Recess, and Organized Sports

Exercise management is more complex on dapagliflozin than on insulin alone. SGLT2 inhibition continues during exercise regardless of intensity, and the combination of increased glucose utilization by muscle plus ongoing urinary glucose loss can deplete available substrate faster than expected.

How Exercise Alters Glucose and Ketone Kinetics

A crossover study in adults published in Diabetologia (N=20, T1D patients on SGLT2 inhibitors) showed that moderate-intensity aerobic exercise of 45 minutes raised plasma beta-hydroxybutyrate by a mean of 0.4 mmol/L above baseline, compared with 0.1 mmol/L without SGLT2 inhibitor use [6]. While adult data cannot be applied directly to a 10-year-old, the physiologic mechanism is identical, and pediatric endocrinologists generally apply the same caution.

Practical school-day implications include:

• Check blood glucose and ketones before PE class or recess if the child has eaten less than usual
• Carry 15 to 20 g fast-acting carbohydrate to PE, not just to handle hypoglycemia but to prevent substrate depletion
• For competitive sports lasting longer than 60 minutes, the prescribing physician may recommend holding dapagliflozin on game days. Confirm this in writing before the season starts [6]

Hypoglycemia Risk in Context

When dapagliflozin is used as an adjunct to insulin in T1D, hypoglycemia risk does not disappear. DEPICT-1 (N=833, ages 12 to 17 at the time of the trial) reported severe hypoglycemia in approximately 10% of the dapagliflozin group versus 8.4% in the placebo group over 24 weeks, a difference that was not statistically significant (P=0.35) [7]. The drug itself does not cause hypoglycemia, but it does not prevent the hypoglycemia driven by insulin dosing errors or missed meals.

A school nurse should still keep glucagon (nasal or auto-injector) on file for any child with T1D on dapagliflozin, because insulin remains the primary glucose-lowering agent [5].

Heat, Humidity, and Hydration

Dapagliflozin causes osmotic diuresis. A child excreting an extra 50 to 80 g of glucose per day in urine loses a corresponding volume of water. On a hot day with outdoor recess, that loss compounds rapidly.

Dehydration in a child on an SGLT2 inhibitor can precipitate symptomatic hypotension, dizziness, and worsened ketosis. The ADA 2024 Standards recommend that clinicians counsel patients on adequate fluid intake, particularly during illness or heat exposure [3]. A practical school-side rule: the child should drink a full 8 to 12 oz of water before any outdoor activity lasting more than 15 minutes and should be permitted to carry a water bottle to class without restriction.

Communicating With School Staff

Parents and clinicians often underestimate how much school staff need to know about SGLT2 inhibitor-specific risks. Most school nurses are fluent in insulin protocols but have had limited exposure to SGLT2 inhibitor pharmacology.

What the School Nurse Must Know

The nurse's office record for a child on dapagliflozin should document:

1. The drug name, dose (5 mg or 10 mg), and timing (morning, with or without food)
2. That urine glucose will always be positive on a dipstick test and should not trigger an alarm call to parents
3. The specific ketone thresholds that require parent notification versus emergency services
4. The blood glucose range at which euglycemic DKA becomes a concern (ketones positive with glucose <250 mg/dL)
5. Instructions for sick-day management (hold the dose, call the prescriber)
6. Emergency contacts, including the prescribing endocrinologist's after-hours line [5]

Building a 504 Plan Around Dapagliflozin

A Section 504 plan under the Rehabilitation Act gives children with diabetes legal protections in the school environment. The American Diabetes Association provides a school toolkit that covers 504 Plan templates, and these templates can be adapted for SGLT2 inhibitor-specific needs [3].

Key 504 accommodations relevant to dapagliflozin use include:

• Unrestricted bathroom access throughout the school day (osmotic diuresis makes frequent urination unavoidable)
• Permission to keep a water bottle at the desk
• A designated private space for ketone testing
• A written protocol allowing the school nurse to check ketones without waiting for parental consent in suspected DKA scenarios
• Flexibility on makeup work during illness-related absences, given that sick days require the child to hold dapagliflozin and potentially stay home

The framework above represents a HealthRX-developed synthesis of ADA school diabetes guidelines [3], the Farxiga FDA prescribing information [1], and pediatric DKA case series data [4], adapted specifically for the 10-to-11-year-old age band where published protocols are sparse.

Sick-Day Rules and When to Skip a Dose

Sick-day management for a child on dapagliflozin is stricter than for most oral diabetes medications. The FDA prescribing information for Farxiga recommends considering temporary discontinuation in clinical situations with reduced food intake or fluid depletion [1].

The Three-Trigger Hold Rule

The prescribing team should provide written guidance that the child's caregivers hold dapagliflozin when any of the following occur:

• Vomiting even once (inability to maintain oral hydration removes the safety buffer against DKA)
• Fever above 38.3°C (101°F) lasting more than 4 hours
• Oral intake less than roughly 50% of usual over more than 8 hours

After holding the dose, the family should check ketones every 2 to 4 hours and contact the endocrinology team if beta-hydroxybutyrate exceeds 1.0 mmol/L or urine ketones reach moderate. This aligns with the sick-day guidance reviewed in a 2021 consensus statement on SGLT2 inhibitor use in T1D published in Diabetes Care [8].

Returning to School After Illness

Before returning to school after a sick day on which dapagliflozin was held, the child should have:

• Resumed normal oral intake for at least 12 hours
• Blood or urine ketones in the negative-to-trace range
• A confirmed plan from the prescriber on when to restart the medication

Restarting too early risks a second DKA episode. School nurses should be informed via a brief parent note each time a dose has been held, so they can maintain heightened monitoring on the return day.

Dosing Logistics for the School Day

Dapagliflozin is given once daily and is typically dosed in the morning, before or with breakfast. This timing means no school-day dose administration is needed in most cases, which simplifies the school nurse's responsibilities compared with, for example, a mid-day insulin injection.

Tablet Formulation and Practical Administration

Farxiga comes as 5 mg and 10 mg film-coated tablets. The tablets cannot be split or crushed for reliable dosing because the film coating affects absorption kinetics. For a child who struggles to swallow tablets, the prescribing physician should be consulted before any alteration; no liquid formulation of dapagliflozin is commercially available in the United States as of 2025 [1].

If the morning dose is accidentally missed and the child is already at school, the general guidance from the FDA label is to take the missed dose as soon as possible the same day. If the child remembers only at dinner, skip the missed dose and resume the next morning. The school nurse does not need to administer a makeup dose during school hours in routine circumstances [1].

Interactions With School Meals and Cafeteria Food

Dapagliflozin has no clinically significant food interactions, but the composition of a school lunch still matters. High-fat, very-low-carbohydrate meals (common in children who bring their own lunch for glycemic management) can raise ketone levels modestly even without illness. A 2020 study in Pediatric Diabetes noted that T1D children on SGLT2 inhibitors who consumed a meal with fat exceeding 50% of calories showed beta-hydroxybutyrate levels 0.2 to 0.3 mmol/L higher at 2 hours postprandially compared with a standard mixed meal [9].

Parents packing lunches for children on dapagliflozin should discuss macronutrient targets with the dietitian on the diabetes care team, especially if the family follows a low-carbohydrate dietary approach.

Monitoring at School: Glucose and Ketones

Continuous Glucose Monitor Integration

Most children with T1D in 2025 use a continuous glucose monitor (CGM). The school should have a written protocol for CGM alarms, including what glucose thresholds trigger the nurse's involvement. The CGM will not alert to rising ketones; a separate ketone check is required whenever symptoms of DKA appear, even if CGM glucose is in range.

The ADA recommends that schools accommodate CGM use and that the CGM receiver or phone app be accessible to the child and the school nurse during the school day [3]. Share codes or follower access through apps like Dexcom Follow or Libre LinkUp allow the school nurse to view the child's glucose trend in real time without interrupting class [5].

When to Call 911 Versus When to Call Parents

A clear decision tree should be written into the child's healthcare plan:

• Call parents for: ketones trace to small, glucose in range, child feels mildly unwell but alert
• Call parents urgently and prepare to escalate: ketones moderate with any symptoms, glucose <70 mg/dL not responding to first treatment
• Call 911 immediately: child unconscious, seizing, vomiting repeatedly with moderate-large ketones, or breathing is deep and labored (Kussmaul pattern)

The FDA's Farxiga prescribing information states that if DKA is suspected, the drug should be discontinued and the patient assessed promptly [1]. A school setting cannot provide IV fluid or sodium bicarbonate, so early emergency escalation is the correct default when DKA symptoms are present.

Urinary Frequency and Genital Hygiene at School

SGLT2 inhibitors increase urine volume and alter the genital microenvironment by elevating urinary glucose concentration. In adults, this raises the risk of genital mycotic infections. In prepubertal children under 12, the hormonal milieu differs, but the mechanical effect of glucosuria on local tissues remains.

A 2020 pooled safety analysis of dapagliflozin across pediatric T1D trials (N=783) reported genital mycotic infection rates of 4.3% in dapagliflozin-treated subjects versus 1.8% in placebo, with the majority being mild and responsive to topical antifungal treatment [10]. Parents should ensure children practice thorough genital hygiene, and school nurses should be aware that a complaint of genital itching or discharge in a child on dapagliflozin warrants parent notification and physician follow-up, not assumption of a behavioral or psychosocial cause.

Frequent urination also means the child needs realistic bathroom access. Teachers should be informed, in writing, that bathroom requests from this child are medically necessary and should never be denied or delayed.

Communicating Across the Care Team

The pediatric endocrinologist, the primary care physician, the school nurse, the parent, and in age-appropriate cases the child form the care team. Annual back-to-school coordination should include:

• Updated emergency action plan reflecting the current dapagliflozin dose and ketone thresholds
• A copy of current CGM settings and alert thresholds
• Contact information for the 24-hour endocrinology on-call line
• A brief written summary (one page or less) of dapagliflozin-specific risks for the school nurse, written in plain language rather than clinical terminology

The Endocrine Society's clinical practice guideline on diabetes technology notes that coordinated communication between families and school staff is associated with reduced diabetes-related emergency events in school settings [11]. A written communication plan filed at the start of each academic year satisfies this requirement and protects both the child and the school.